IS ANTI-FACTOR XA MONITORING BETTER THAN ACTIVATED PARTIALTHROMBOPLASTIN TIME (APTT) IN ACHIEVING THERAPEUTIC RESPONSE TO UNFRACTIONATED HEPARIN?

被引：0
|
作者：
Manzanades, Yuri [1 ]
机构：
[1] West Middlesex Univ Hosp, Isleworth, England
来源：
NURSING IN CRITICAL CARE | 2021年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：30 / 31
页数：2
相关论文
共 50 条
  • [1] SAFETY OF MONITORING UNFRACTIONATED HEPARIN INFUSIONS IN CRITICALLY ILL PATIENTS: ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)
    Burka, Abigail
    Cunningham, Michael
    Ernst, Neil
    Droege, Chris
    Hillebrand, Kristen
    Clark, Lindsey
    Tsuei, Betty
    Mueller, Eric
    [J]. CRITICAL CARE MEDICINE, 2012, 40 (12) : U279 - U279
  • [2] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [3] Anti-factor Xa assay versus aPTT for the monitoring of unfractionated heparin infusions in patients treated for cardiac indications
    Marston, Matthew, Jr.
    Heath, Emily
    Ford, Renee
    Griffin, Lukas
    Boudreau, Marybeth
    [J]. PHARMACOTHERAPY, 2013, 33 (10): : E190 - E191
  • [4] Comparing anti-factor Xa and activated partial thromboplastin levels for monitoring unfractionated heparin.
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly
    [J]. PHARMACOTHERAPY, 2018, 38 (07): : E54 - E54
  • [5] Anti-Xa concentration better than activated partial thromboplastin time for the monitoring of unfractionated heparin treatment
    Moumneh, T.
    Mallecian, Y.
    Calmes, A.
    Lacour, E.
    Roy, P. M.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 360 - 361
  • [6] Comparison of Activated Partial Thromboplastin Time (aPTT) and Anti-Factor Xa for Low Intensity Unfractionated Heparin Monitoring in Patients with Mechanical Circulatory Support Devices (MCSD)
    Volod, O.
    Lam, L. D.
    Barglowski, M.
    Mirocha, J.
    Runyan, C.
    Moriguchi, J.
    Czer, L. S.
    Arabia, F.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S443 - S443
  • [7] Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation
    Vo, Tai
    Bello, Abdel
    Ragan, Monika
    Flanagan, James
    Johnson, Darriel
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 : S77 - S83
  • [8] Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Toulon, Pierre
    Smahi, Motalib
    De Pooter, Neila
    Zereg, Elamine
    [J]. BLOOD, 2017, 130
  • [9] Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Cuker, Adam
    Ptashkin, Beverly
    Konkle, Barbara A.
    Pipe, Steven W.
    Whinna, Herbert C.
    Zheng, X. Long
    Cines, Douglas B.
    Pollak, Eleanor
    [J]. BLOOD, 2008, 112 (11) : 166 - 166
  • [10] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    Cuker, A.
    Ptashkin, B.
    Konkle, B. A.
    Pipe, S. W.
    Whinna, H. C.
    Zheng, X. L.
    Cines, D. B.
    Pollak, E. S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 80 - 86
12345